应用HLA—B＊5701等位基因药前筛查阿巴卡韦超敏反应  

HLA-B＊5701 screening for hypersensitivity to abacavir

作　　者：李星美[1] 姚均[1] 

机构地区：[1]中国疾病预防控制中心性病艾滋病预防控制中心,北京102206

出　　处：《中国艾滋病性病》2011年第1期85-87,91,共4页Chinese Journal of Aids & STD

基　　金：十一五重大专项

摘　　要：阿巴卡韦超敏反应(ABC HSR),是欧美国家临床应用抗艾滋病药物阿巴卡韦时,少数病例发生的过敏性多器官综合征,2001年发现,HLA-B*5701等位基因与阿巴卡韦超敏反应密切相关。发现这一基因位点后,诸多的研究致力于解决一个问题,即能否将HLA-B*5701等位基因筛查应用于临床,在阿巴卡韦用药前进行筛查,从而排除潜在的超敏反应患者,避免因服用阿巴卡韦带来的危害。文章综述了HLA-B*5701基因筛查从发现到临床应用所经历的发展过程,以及在国际上的研究现状。Abacavir hypersensitivity reactions （ABC HSR） is a multi-organ hypersensitivity syndrome caused by abacavir which has been prescribed for the treatment of HIV infection in the West. In 2001 a strong predictive asso-ciation of carriage of HLA-B ＊ 5701 allele with abacavir hypersensitivity reactions was described. Afterwards , a large number of studies were designed to establish the effectiveness of prospective HLA-B ＊ 5701 screening to prevent the hypersensitivity reaction to abacavir. This review focuses on the development of HLA-B ＊ 5701 genetic screening as a means of preventing drug hypersensitivity reactions and the international current research situation.

关 键 词：阿巴卡韦 超敏反应 艾滋病病毒 皮肤斑贴实验HLA-B＊5701 

分 类 号：R512.91[医药卫生—内科学]